Exhibit 10.18
January 3, 2023 Robert J. Gould Dear Robert:
Fulcrum Therapeutics, Inc. (the “Company”) is pleased to extend you a consulting role as Interim Chief
Executive Officer of the Company (“Interim CEO”), reporting to the Board of Directors of the Company (the “Board”), effective January 3, 2023 (the “Effective Date”). The terms are as follows:
$600,000 per year, payable at the monthly rate of $50,000 in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings (the “Base Salary”). The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices.
Termination and (ii) any unpaid expense reimbursements on or before the time required by law but in no
1
ACTIVE/120625975.1
event more than 30 days after the Date of Consulting Services Termination (together, the “Accrued Obligations”). Other than the Accrued Obligations, you will not be entitled to any compensation from the Company in connection with the ending of your consulting services.
[Signature page follows.]
2
ACTIVE/120625975.1
Thank you for your willingness to serve as the Interim CEO. You may indicate your agreement with these terms by signing and dating this Agreement, together with the signed Restrictive Covenants Agreement, and returning them both to me. If you have any questions, please do not hesitate to contact me.
Very truly yours,
| By: | /s/ Kate Haviland |
|
|
|
| Name: | Kate Haviland |
|
|
|
| Title: | Chair, Board of Directors |
I have read and accept this Agreement:
| By: | /s/ Robert J. Gould |
|
|
|
| Name: | Robert J. Gould |
3
ACTIVE/120625975.1